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INTRODUCTION
Alveolar soft part sarcoma (ASPS) is a rare malignant
soft tissue tumour that accounts for about 1% of all
soft tissue sarcomas.1,2 It was first described in 1952
by Christopherson and Stewart.3 Despite numerous
studies since then, the histiogenesis, biologic behavior
and best treatment modality has remained debatable.
The head and neck region is the favored site for ASPS
in children and adolescents while the thigh and buttocks
are common sites for ASPS in adults.4-6 Also, a female
predilection has been reported in cases occurring in
the 1st and 2nd decades of life while a slight male
preference was observed after the 3rd decade.7-9
Presentation of ASPS is usually that of a slow growing
painless mass, with a high rate of metastasis to the
lungs, bone, and the brain, which could occur long
after excision of  the primary tumour.2,7,10 ASPS could
present clinically as a vascular lesion and magnetic
resonance imaging (MRI) of the tumour with contrast
enhancement is ideal to demonstrate its vascular
nature11-13 whilst differentiating it from other
vascularized tumours.
Microscopically, ASPS consists of  large polygonal to
round cells with distinctive cell membrane, abundant
eosinophilic granular cytoplasm, round to oval
eccentric nuclei with prominent nucleoli which may
be multiple. Neoplastic cells are characteristically
disposed in nested or organoid growth pattern
separated by thin fibrous septa.6,14,15 The cells may
appear non-cohesive, giving it the alveolar pattern.
Those without organoid patterns have also been
described as well as those with clear cytoplasm. The
solid pattern is more frequently seen in pediatric cases.16
The tumour is well vascularized by delicate sinusoidal
vascular channels lined by a single layer of endothelial
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were the most common immunohistochemical stains used and were both
expressed 7 out of 8 cases (87.5%). Most common treatment modality was
surgery and 42 (82.4%) cases managed by surgery alone were free of  disease at
< 5 years of follow up.
Conclusions: TASPS slightly affected the female gender and tongue base more
commonly. It occurred more in the first two decades of  life. Use of  standard
investigative tools for management will allow for better appraisal of research
findings.
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cells. Pleomorphism and mitosis are infrequent. About
80% of ASPS have intracytoplasmic, periodic acid–
schiff positive, diastase-resistant rhomboid- or rod-
shaped crystals.16
Furthermore, ASPS have been reported to commonly
occur on the tongue in many studies, as well as in case
reports and constitute 25% of  all ASPS.17-21 Also,
tongue alveolar soft part sarcoma (TASPS) occurs in
patients much younger than those for ASPS from other
anatomical locations particularly in females.2, 18, 22, 23
There are many reports describing the clinico-
pathologic features of  ASPS.10, 18, 24 However, there is
a dearth of literature analyzing these features in tongue
tumours only, despite the tongue being a common
site of presentation in the head and neck region.
Therefore, it is desirable to assess the characteristics
of TASPS and to assess the available treatment
modalities necessary to achieve a desirable outcome in
the management of  this entity. This study aims to
describe the essential clinico-pathologic features,
treatment modalities and outcome of previously
reported TASPS by conducting a scoping review along
with present cases seen at the Oral Pathology
Department, University College Hospital, Ibadan.
MATERIALS AND METHODS
Study design
This study was a review of previous studies describing
the clinico-pathologic features of  TASPS. A scoping
review was conducted because the available studies
on TASPS varied in their methods and data, thus
precluding the conduct of  a meaningful meta-analysis.
The review was performed following the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses extension for Scoping Reviews (PRISMA-
ScR) Checklist.25
Methods
The histopathology records of  the Department of
Oral Pathology, University College Hospital (UCH),
Ibadan over a period spanning 26 years were examined.
All entries of cases diagnosed as ASPS were retrieved,
while TASPS were identified for analysis. The
haematoxylin and eosin (H&E) slides of these cases
were retrieved and reassessed to verify the diagnosis.
Case files of eligible cases were retrieved and
information on bio data, duration of  symptoms,
symptoms on presentation, presence of tumour spread
or metastasis at diagnosis, site of metastasis if present,
clinical impression, treatment received, duration of
follow up and status at follow up were obtained, cases
with incomplete records were excluded from the study.
Literature search
To identify relevant studies, an all-inclusive search of
the databases (PubMed, Medline, Cochrane and
Google Scholar) as well as an internet search of articles
written in English language was conducted between
August and October 2019. Keywords used for the
search included a blend of “alveolar soft-part sarcomas
(ASPS),” “soft-tissue tumours.” and/or “tongue.” Also,
relevant citations identified in the reference lists of
selected articles were included in the search. The search
lists from the electronic sources were merged and
duplicates were removed. The title and abstract of
the identified articles were screened to remove studies
outside the scope of this review after which the full
text of all potentially eligible articles were retrieved
for further analysis. Articles that did not satisfy the
inclusion criteria were excluded from further
consideration. Also, a manual search of  bibliographies
of identified articles was done by cross referencing
eligible publications on ASPS from 1957 till date while
relevant citations identified in the reference lists of
selected articles were included in the search to identify
additional studies of interest. The selection process is
displayed in a flow chart (Figure 1).
Criteria for eligibility
Articles included were human case reports/case series,
letter to editors and review articles on ASPS of the
tongue either in whole, or as part of  a series on ASPS.
Articles that were not available in English or which the
full text could not be obtained were excluded from
the study. Similarly, ASPS that metastasized to the
tongue as well as cases with incomplete data were
excluded from the study.
Extraction of data
A proforma was used to extract data from eligible articles
by two investigators (AOA, BFA) independently.
Information extracted included clinico-pathological and
demographic data such as year of publication, country
of  publication, type of  study, patients’ age, gender, location
and surface of tongue affected, duration of symptoms,
symptoms on presentation, presence of tumour metastasis
at diagnosis, site of metastasis if present, clinical impression,
result of immunohistochemical studies (when available),
treatment type, duration of follow up and status of
patients at last follow up. Any inconsistencies were resolved
by consensus with a third investigator (GOO).
Statistical analysis
Descriptive statistics was used for analysis. Relevant
data were extracted from the included studies and
variables were presented using summary statistics and
tables. Data analysis was done using SPSS software
version 21 (IBM Corporation, Armonk, NY, USA).
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RESULTS
Initial electronic search of the databases identified 29
potentially eligible articles. An additional 31 publications
were identified from other sources (bibliography of
initially identified articles). After initial review of the
titles and abstracts, four duplicate articles were
removed and 56 articles which met the inclusion criteria
were identified. Eight of these were excluded because
two were not written in English language, while full
text articles were unobtainable for another six. Also,
one eligible article was identified and included following
a hand search. Thus, a total of 49 articles (39 case
reports and 10 case series) were utilized in this study.
Furthermore, five cases of  ASPS were identified from
the records of  Oral Pathology Department, UCH,
Ibadan. Four affected the tongue, while one affected
the cheek and was excluded from further analysis. The
age range of cases was 6 to 34 years; while male to
female ratio was 3:1. Also, the site of  predilection was
the dorsal surface of the anterior tongue (Figure 2).
Duration of symptoms ranged from three months to
four years with tumours in the anterior dorsum and
sulcus terminalis areas having a shorter duration than
posterior and ventral tongue tumours.
Histopathology of  all cases showed tissue disposed in
organoid pattern of large round to oval eosinophilic
cells separated by moderately to highly vascularized
fibrous connective tissue stroma. Individual cells have
abundant granular cytoplasm with some having
eccentric nuclei while others had vesicular nuclei, (Figure
3). The clinical data of the present cases have been
summarized in Table 1.
the mean age of cases was 13.9 ± 12.2 years while the
mode was 3 years and median age was 11 years.
Patients’ age at presentation ranged from 11 months
to 64 years and most cases (38/46.9%) occurred in
the 1st decade followed by the 2nd (24/29.6%) and 3rd
(12/14.8%) decades and declined gradually to one case
in the 7th decade (Table 3).
On the tumour location, only 48/81 (59.3%) cases
reported the location of tumour on tongue. The base
was involved in 19/48 (39.6%) followed by the lateral
border 13/48 (27%) and anterior tongue- 8/48
(16.6%) cases. Other tongue sites were recorded as
follows: posterior tongue- 2/48 (4.2%), sulcus
terminalis- 2/48 (4.2%), mid-portion- 2/48 (4.2%),
root- 1/48 (2.1%) and anterior to base- 1/48 (2.1%).
Also, only 32/81 (39.5%) cases reported the surface
of the tongue affected. The dorsum was the most
common tongue surface affected in 22/32 (68.8%)
cases while the ventral surface was involved in 10/32
(31.2%) cases.
Furthermore, only 35/81 (43.3%) cases recorded the
duration of disease from onset of disease to time of
hospital presentation. All the patients presented within
one to 84 months of onset of symptom, with a median
duration of 6 months (Interquartile range 9 months).
Also, 65/81 (80.2%) cases had tumour size
documented; either clinical or gross surgical specimen,
in which only 3 cases (4.6%) had tumour size greater
than 6.5 cm. Mean tumour size obtained was 2.9 ±
1.9 cm in the widest dimension, while the size range
was 0.8 to 8 cm. Additionally, clinical impression of  a
benign lesion was made in 33/81 (40.7%) cases and
these were mainly constituted by haemangioma 12/
Case Gender Age Site Surface Duration Size
(cm)
Treatment Follow up Status at
follow up
1 Male 29 Sulcus terminalis Dorsum 3 months NR NR NR LTFU
2 Male 6 Anterior Dorsum 3 months 6 Surgery 13 months FOD
3 Female 34 Anterior Dorsum 6 months 5 None 19 months DOD
4 Male 17 Posterior Dorsum 48 months NS None 12 months AWD
Table 1: Characterization of  TASPS in Ibadan
NR – No record; LTFU – Lost to follow up; FOD – Free of  disease; DOD – Died of  disease; AWD – Alive with disease
In all, 77 cases from 49 articles and four cases from
records of  Oral Pathology Department, UCH, Ibadan
(totaling 81 cases) were used. Table 2 shows a list of
the publications and the number of  cases.3,5,17,18,26-69
Asian studies accounted for 35 (43.2%) cases, while
North American and European studies recorded 25
(30.9%) and 12 (14.8%) cases respectively (Figure 4).
There was a slight female preponderance of 1.1 and
33 (36.4%) followed by granular cell myoblastoma/
tumour 6/33 (18.2%) and dermoid cyst 2/33 (6%).
Only 54/81 (66.7%) cases recorded the presence or
absence of tumour metastasis either at presentation
or at any point during treatment. Tumour metastasis
was present in 14/54 (25.9%) cases, while it was not
seen in 40/54 (74.1%) cases. Also, the most common
site of tumour metastasis were regional lymph nodes
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Figure 1: Flow chart for scoping review









Table 3: Age distribution of  cases in decades
and the lungs, both recording 6/14 (42.8%) and 4/14
(28.6%) respectively. The lungs and the liver as well as
the lungs and lymph nodes were affected in one case
each, while disseminated disease occurred in 2/14
(14.3%) cases.
Immunohistochemical studies became more
established in the last two to three decades of this
review and were performed in 37/81 (45.6%) cases
in which 33/37 (89.2%) cases were stained using the
Table 4: Treatment modalities of  TASPS cases
Treatment type Frequency Percentage
Surgery only 51 63.0
Surgery and chemotherapy 11 13.6




No treatment 2 2.5
Chemotherapy only 2 2.5
Chemotherapy and
radiotherapy 1 1.2









following antibodies: Transcription Factor E3 (TFE3)
- (8/24.2%); Neuron Specific Enolase (NSE) - (8/
24.2%); desmin (7/21.2%); actin (5/15.2%) and
vimentin (5/15.2%) while four cases stained negative
to all the immunohistochemical stains used.
Interestingly, TFE3 and NSE were both expressed 7
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Figure 2: Clinical pictures of 6 year old male, A and B shows dorsal swelling of the tongue, C shows surgical
specimen and D shows tongue one-week post operatively.
Figure 3: Histopathology of  TASPS cases in Ibadan. Photomicrograph shows (A) - solid pattern having tissue
disposed in organoid arrangement, separated by vascularized fibrous septae H & E X 40; (B) - shows large
oval to round eosinophilic cells H & E X 100 and (C) – shows non-cohesive individual cells having abundant
granular cytoplasm H & E X 400
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out of 8 cases (expression rate of 87.5%) while desmin,
actin and vimentin were expressed 5 out of 7 (71.4%),
4 out of 5 (80%) and 3 out of 5 (60%) cases
respectively. Polymerase chain reaction was also used
in three instances to detect the presence of TFE3.
Most common treatment modality was surgery in 51
(63%) cases, followed by surgery + chemotherapy in
11 (13.6%) cases and surgery + radiotherapy in 6 (7.4%)
cases (Table 4). Subsequently, 42/51 (82.4%) cases that
were managed by surgery alone were free of disease
at <5 years of follow up while 9/51 (17.6%) were
free of disease at >5 years of follow up. All the
patients (4 cases) that had follow up for over 300
months, who had surgery alone, had either “no
evidence of the disease” or “were free of the disease”
at the last follow up.
DISCUSSION
The present study presents an effort to characterize
TASPS by giving a synopsis of its clinico-pathologic
features from when it was first reported till date and
present cases seen at our center. Our major findings
include the following: Asian studies dominated the
cases seen in this study, with Wang et al. 64 contributing
10 cases having tongue involvement out of a series of
18 patients with ASPS of the oral and maxillofacial
region. Increased incidence of TASPS on the Asian
continent may be due to the relatively large population
of  Asia. Tongue ASPS slightly affected the female
gender more commonly and about 76.5% of cases
were diagnosed in the first two decades of life,
subsequently showing a steady decline in incidence with
advancing age. The base of the tongue is the most
common location involved, while the dorsum is the
most frequently affected surface. Interestingly, it was
initially considered to be a benign lesion in some case
reports and tumour metastasis occurred in 25.9% of
cases that reported presence of  metastasis. Also, TFE3
and NSE immunohistochemical stains had equal
expression rates while surgery was the most common
treatment modality.
In the present review, some findings differed from
those in a previous review of 14 lingual ASPS by
Fanburg-Smith et al.18 which to the best of our
knowledge was the largest series on TASPS in English
literature. Slight female preponderance was seen in the
present study which differed from a male
preponderance reported by Fanburg-Smith et al.18
Some authors have previously referred to ASPS as a
disease of childhood while some have referred to it
as a disease of childhood and adolescence4, 6, 18. In the
present study, majority of  ASPS occurred in the first
and second decade of life but few also occurred in
other age groups up to the 7th decade. Also, Fanburg-
Smith et al.18 recorded a median age of five years while
this study recorded a median age of  11 years. Similarly,
the age range in this review was 11 months to 64 years
while Fanburg-Smith et al.18 recorded a range of 3 to
21 years. The findings in this review, however concurs
with the findings in a study of ASPS of the oral cavity
by Shelke et al.24 where an age range of 1.5 – 64 years
was reported. Similarly, the finding in this study on
female predilection is in agreement with the outcome
in the study of Shelke et al.24 where a female
predilection for TASPS was also reported. It is
probable that our larger sample size comprising of
Figure 4: Distribution of TASPS cases according to continent
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subjects from wider and diverse socio-cultural-
geographic background may be responsible for the
noted differences and may be more representative of
the characteristic of  TASPS.
Additionally, the findings of  the base and dorsum of
the tongue, as the prevalent location and surface
affected in this study, were in line with the results
obtained by Shelke et al.24. Much is yet to be understood
in the preference for the tongue by ASPS in the head
and neck region and the predominance of the
involvement of the base as well as the dorsal surface
of  the tongue. The base of  tongue serves as the
posterior opening of the oral cavity as well as the access
to the pharynx and esophagus, and the lower aspect
of the nasopharynx. It is composed of sub-mucosal
lymphoid tissue (lingual tonsils) and deep tongue
muscles in charge of  movement. Also, this region may
play a role as a sump area for carcinogens and irritants.
Whether a link exists between the anatomy of the base
of the tongue and the preference of TASPS for this
location would be a useful focus of future research.
Also, most of  the ASPS in this review were relatively
small in size, in agreement with the previous study by
Fanburg-Smith et al.18. Due to the location and function
of the tongue, it is likely to have an early presentation
with a small tumour size either due to discomfort,
abnormal sensation, or interference with function
which may make the patient seek help early.
ASPS like many soft tissue tumours lack specific
immunohistochemical markers, which reflected in the
use of a wide range of antibodies in various reports
collated in this study. ASPS has been previously
reported to show infrequent immunoreactivity for
desmin70 and MyoD171 suggesting skeletal muscle
differentiation. Our findings in this study revealed that
various antibodies were randomly expressed in the
different studies.
Nevertheless, ASPS is now believed to be a specific
chromosomal alteration, der(17)t(X:17)(p11:q25), owing
to the fusion of the TFE3 transcription factor gene
with the alveolar soft part sarcoma critical region 1
(ASPSCR1)6. The use of real-time polymerase chain
reaction and fluorescent in situ hybridization in
identifying fusion transcript ASPSCR1-TFE3 and TFE3
rearrangement respectively, are regarded as efficient ways
for diagnosis6. Similarly, this same fusion gene has been
implicated in a section of translocation associated renal
cell carcinomas (RCCs)6. However, the translocation in
ASPS is unbalanced while that of translocation
associated RCCs are balanced.6 Also, the ASPSCR1-
TFE3 fusion protein plays the role of a deviant
transcription factor leading to the activation of the MET
signaling pathway known to stimulate angiogenesis and
cell proliferation6. In addition, antibodies to TFE3 exhibit
nuclear positivity in ASPS; similar to findings in some
translocation-associated renal cell carcinomas (RCCs),
perivascular epithelioid cell neoplasm (PEComa) and
granular cell tumours.72-75
Curiously in this study, antibodies to TFE3 and NSE
were used in equal number of cases and expression
rate was 87.5% for each. This finding suggests that
more studies would be needed to verify if NSE has a
role as a reliable marker for ASPS.
Alveolar soft part sarcoma was previously reported
to have a high rate of metastasis especially to the lungs,
bone and the brain.2,7 However, in this review, the
reported rate of metastasis for TASPS was found to
be lower than expected at 25.9% of studies that
reported metastasis. Also one of  the cases that
presented in our center who was yet to have any form
of treatment, has lived with the disease for sixty months
without evidence of  metastasis. Adjudging that the
presence of metastasis is usually seen as an indicator
for malignancies, it is unclear whether TASPS represents
an entity with better prognosis than ASPS in other parts
of  the body.
Furthermore, surgical management was the most
common treatment modality employed in many
studies in this review; either alone or in combination
with other treatment modalities. All cases (four in all)
that were followed up for over 300 months with
tumour sizes ranging between 1.3 cm to 5 cm, had
surgery alone and had no evidence of the disease or
metastasis as at the last follow up. As opined by
Fanburg-Smith et al.18, early diagnosis and small tumour
size may be factors that influence the relatively good
outcome associated with ASPS.
Study limitations
The differences in the mode of presentation of the
cases posed a challenge in data retrieval and analysis
since there is no uniform benchmark for case reports
and series. This led to heterogeneity of  results, making
it challenging to pool findings from the studies
included and to draw definitive conclusions from this
study. Also, the cases described here may not constitute
the entirety of TASPS (perhaps due to under-reporting
and inaccessible full articles). However, they probably
do comprise the majority of cases worldwide.
CONCLUSION
Summarily, this study has provided an up to date brief
of  TASPS. Tongue ASPS slightly affected the female
gender more commonly and occurred more in the
first two decades of  life. Also, the base of  the tongue
was the most common location affected while surgical
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management was mostly used for treatment and cases
managed by surgery alone were free of disease at <5
years of  follow up. Use of  gold standard investigative
tools for diagnosis and for follow up will allow for
better appraisal of  research findings. Longitudinal
follow up of cases will also help in better understanding
of this disease entity as well as the optimum treatment
modality. Thus, clinicians should be suspicious of
indolent appearing tongue lesions and expedite
histologic assessment even when a benign lesion is
suspected. This is more so when a hemorrhagic tongue
swelling is being considered.
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